β 2-Glycoprotein I and anticardiolipin antibody binding to resting and activated cultured human endothelial cells

Journal of Rheumatology

Volumn 23, Issue 9, 1996, Pages 1543-1549

  Hanly, John G ^a,c   Hong, Connie ^d   Issekutz, Andrew ^b  

^a Division of Rheumatology   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d NONE

Author keywords

2 glycoprotein I; Anticardiolipin antibody; Antiphospholipid antibody; Antiphospholipid antibody syndrome; Endothelial cells; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; BLOOD; BLOOD PHYSIOLOGY; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029770715     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Sammaritano LR, Gharavi AE, Lockshin MD: Antiphospholipid antibody syndrome: Immunologic and clinical aspects. Semin Arthritis Rheum 1990;20:81-96.
2. Harris EN: Annotation: Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.
3. Love PE, Santoro SA: Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990;112:682-98.
4. Alarcón-Segovia D, Sanchez-Guerrero J: Primary antiphospholipid syndrome. J Rheumatol 1989;16:482-8.
5. Krilis SA, Hunt JE: Immunology of antiphospholipid antibodies. In: Panayi GS, ed. Immunology of Connective Tissue Diseases (Immunology and Medicine series). Boston: Kluwer Academic, 1993.
6. McNeil HP, Chesterman CN, Krilis SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193-280.
7. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:120-4.
8. Galli M, Comfurius P, Maassen C, et al: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
9. 2-glycoprotein I (apolipoprotein H) as cofactor. J Rheumatol 1992;19:1397-402.
10. 2 glycoprotein I as cofactor in the binding of IgM and IgA anticardiolipin antibodies. J Rheumatol 1995;22:1091-6.
11. 2-glycoprotein I: Localization of the disulfide bridges. Biochemistry 1992;31:3611-7.
12. Schousboe I: Beta 2-glycoprotein 1 : A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985;66:1086-91.
13. Nimpf J, Bevers EM, Bomans PH, et al: Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein I. Biochim Biophys Acta 1986;884:142-9.
14. Nimpf J, Wurm H, Kostner GM: Beta 2-glycoprotein-1 (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1957;63:109-14.
15. 2-Glycoprotein-I is a cofactor for antibodies reacting with five anionic phospholipids (letter). J Rheumatol 1995;22:2009.
16. Harris EN, Gharavi AE, Loizou S, et al: Cross reactivity of antiphospholipid antibodies. J Clin Lab Immunol 1985;16:1-6.
17. Ansell GB, Spanner S: Phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine. In: Kuo JF, ed. Phospholipids and Cellular Regulation. Boca Raton, FL: CRC Press; 1985.
18. Barenholz Y, Gatt S: Sphingomyelin: Metabolism, chemical synthesis, chemical and physical properties. In: Hawthorne JN, Ansell GB, ed. Phospholipids. Amsterdam: Elsevier, 1982:129-77.
19. Zwaal RFA, Hemker HC: Blood cell membranes and haemostasis. Haemostasis 1982;11:12-39.
20. Chesterman CN, Chong BH, Shi W: Pathogenic potential of antiphospholipid antibodies: Binding to human platelets (abstr). Thromb Haemost 1991;65:555A.
21. Tan EM, Cohan AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. 2-glycoprotein-I. J Immunol Methods 1994;175:107-14.
23. 2-glycoprotein-I in the rat: Isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980;11:265-70.
24. Issekutz A, Lopes N: Effect of ebselen on polymorphonuclear leukocyte adhesion to and migration through cytokine-activated vascular endothelium. Int J Immunopharmacol 1992;14:1383-90.
25. Morzycki W, Sadowska J, Issekutz A: Interleukin-1 and tumour necrosis factor a induced polymorphonuclear leukocyte-endothelial cell adhesion and transendothelial migration in vitro: The effect of apical versus basal monolayer stimulation. Immunol Lett 1990;25:331-40.
26. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-6.
27. 2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994;95:310-5.
28. 2- glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995;22:1894-8.
29. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457-62.
30. 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994;21:1684-93.
31. 2 glycoprotein I to platelets: Effect of adenylate cyclase activity. Thromb Res 1980;19:225-37.
32. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta- 2-glycoprotein-I critical for lipin-binding and anticardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993;90:2141-5.
33. 2-glycoprotein I contains a phospholipid binding site (Cys281 - Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994;152:653-9.
34. 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol 1995;13:179-85.
35. Del Papa N, Meroni PL, Tincani A, et al: Relationship between anti- phospholipid and anti-endothelial cell antibodies: Further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 1992;10:37-42.
36. 2- glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus 1995;4:179-86.
37. LaSala J, Lo SK, Salmon J, Gharavi A, Sammaritano L, Silverstein RL: Activation of vascular endothelium by antiphospholipid antibodies: Induction of an adhesive phenotype for monocytes (abstr). Arthritis Rheum 1994-(suppl)37:S286.
38. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-15.
39. Alarcón-Segovia D, Llorente L, Ruiz-Arguelles A, Richaud-Patin I, Perez-Romano B: Penetration of anti-DNA antibodies into mononuclear cells causes apoptosis (abstr). Arthritis Rheum 1995;(suppl)38:S182.
40. Goldman D, Philips G, Back K, Petri M: Binding of SLE antibodies to apoptotic endothelial cells (abstr). Arthritis Rheum 1995;(suppl)38:S214.
41. Rosen A, Schlissel M, Petri M, Casciola-Rosen L: Antiphospholipid antibodies bind to the surface of apoptotic cells and abolish their procoagulant activity (abstr). Arthritis Rheum 1995;(suppl)38:S267.